Brain tumours are among the most devastating cancers that remain resistant to therapy and pose major health problems throughout the world. There are numerous types of brain tumours identified in humans with varying biological and clinical outcomes. Glioblastoma is one of the most frequent primary malignant brain tumours in adults. It is estimated that median survival is generally less than 1 year, and most patients die within 2 years from the time of diagnosis ([@bib15]). Standard therapy includes surgical resection followed by radiation and chemotherapy, which have limited efficacy and significant side effects ([@bib34]). Multi-drug resistance and fast recurrence are some of the key challenges in combating brain tumours. Thus, further investigations are needed to develop novel therapeutic strategies for the treatment of brain tumours in patients. Cancer stem cells (CSCs) are a small population of cancer cells that exhibit characteristics of typical stem cells, such as asymmetric division, self-renewal, proliferation, and tumour-initiation capabilities. The CSCs were first identified in acute myeloid leukaemia ([@bib5]), and then in breast ([@bib1]), prostate ([@bib33]), liver ([@bib49]), and skin cancer ([@bib39]). Earlier studies have also identified putative brain tumour stem cells (BTSCs) on the basis of their ability to form tumour spheres and the expression of neural stem cell marker CD133 ([@bib44]; [@bib45]). The failure to cure cancer has been attributed to the fact that conventional therapies target rapidly growing tumour cells, which respond transiently, whereas sparing CSCs ([@bib26]). Thus, optimal treatment for glioblastoma requires targeting the self-renewal capabilities of BTSCs, which are responsible for tumour recurrence and progression in patients.

Two important growth factors commonly used to maintain the self-renewal of embryonic stem cells (ESCs), neural stem cells (NSCs), and BTSCs are epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF; [@bib48]). These growth factors induce a complex network of multiple signalling pathways, leading to the expression of stemness gene clusters associated with the self-renewal of stem cells. Stemness genes encode for a group of proteins that have critical roles in maintaining the pluripotency of ESCs ([@bib47]; [@bib50]). Ectopic expression of SRY (sex determining region Y)-box 2 (Sox2) in conjunction with the octamer-binding transcription factor 4, also known as POU5F1 (POU domain, class 5, transcription factor 1; Oct4), nanog homeobox (Nanog), and Lin28 was sufficient to induce reprogramming of human fibroblasts into induced pluripotent stem cells with all the essential characteristics of ESCs ([@bib50]; [@bib46]). The SRY box 2 (Sox2) is an SRY-related high-mobility group box transcription factor that is expressed in the ESCs, NSCs, and trophoblast stem cells, but not in their differentiated derivatives ([@bib3]; [@bib13]; [@bib8]; [@bib16]). Gene targeting experiments have shown that the *Sox2* expression is required to maintain pluripotency of stem cells during early embryonic development ([@bib3]). More importantly, constitutive expression of Sox2 maintains stemness and inhibits neuronal differentiation ([@bib20]). Nanog is a homeobox protein, which in combination with Oct4 and Sox2, constitutes a core transcription complex that maintains the self-renewal and stemness characteristics of human ESCs ([@bib7]). Interestingly, earlier studies have demonstrated the expression of many stemness genes, including *Sox2* and *Nanog*, in human glioma-derived BTSCs ([@bib21]), suggesting their significance to the self-renewal and tumourigenicity of glioblastoma.

Peroxisome proliferator-activated receptor (PPAR) is a family of ligand-dependent nuclear receptor transcriptional factors that regulate physiological processes ranging from development to reproduction, metabolism, cell proliferation, differentiation, apoptosis, and homeostasis. Three known subtypes of the PPAR family are PPAR*α*, PPAR*γ*, and PPAR*δ* ([@bib23]). The PPAR*γ* is abundantly expressed in many cell types, where it regulates lipid metabolism, glucose homeostasis, tumour progression, and inflammation. Polyunsaturated fatty acids, eicosanoids, prostaglandins, and linoleic acid have been identified as endogenous ligands for PPAR*γ*, whereas thiazolidinedione class of compounds function as high-affinity synthetic agonists for PPAR*γ* ([@bib37]). Upon activation with specific ligands, PPAR*γ* forms a heterodimer complex with retinoid X receptor, which then mediates the target gene expression ([@bib42]). Because of its physiological significance, PPAR*γ* has been explored as a therapeutic modality for various diseases ([@bib4]). Earlier studies have shown that PPAR*γ* agonists induce growth arrest and apoptosis in glioma cells in culture, suggesting their use in the treatment of brain tumours ([@bib30]). In a recent report, we showed that PPAR*γ* agonists 15-deoxy-Δ^12,14^-ProstaglandinJ~2~ (15d-PGJ2) and ciglitazone inhibit growth and expansion of CD133^+^ BTSCs in culture ([@bib10]), but the mechanism by which PPAR*γ* agonists regulate BTSCs is not known.

In this study, we investigated the molecular mechanisms by which PPAR*γ* agonists regulate BTSCs in culture. We found that PPAR*γ* agonists alter the expression of various stemness and differentiation genes, suggesting the significance of PPAR*γ* in the treatment of glioblastoma.

Materials and methods
=====================

Glioma cell culture
-------------------

Human glioblastoma cell line T98G was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). DB29 primary human glioma cells were established in our laboratory by culturing surgically removed brain tumour tissue samples obtained from the tissue repository at Methodist Research Institute with an IRB approved protocol. Glioma cells were cultured in Dulbecco\'s modified Eagle medium (DMEM) with 10% FBS, 1 mℳ sodium pyruvate, 100 U ml^−1^ penicillin G, 100 *μ*g ml^−1^ streptomycin, 2 mℳ glutamine, 1 mℳ MEM non-essential amino acids, and 50 *μ*ℳ 2*β*-mercaptoethanol in 5% CO~2~ incubator at 37 °C. The cells were dissociated using 0.25% trypsin with 0.05 mℳ EDTA solution and sub-cultured once in 3--5 days ([@bib10]; [@bib9]).

Brain tumour stem cell culture
------------------------------

To induce the growth and expansion of BTSCs as gliospheres, we adopted a culture condition established in our laboratory ([@bib10]; [@bib9]). Briefly, T98G and DB29 glioma cells were cultured in neurobasal medium (NBM) supplemented with B27 (Invitrogen, Madison, WI, USA) in the presence of 10 ng ml^−1^ EGF (PeproTech, Rocky Hill, NJ, USA) and bFGF (R&D Systems, Minneapolis, MN, USA). The BTSCs (5 × 10^4^ ml per well) were cultured in 12-well plates in 5% CO~2~ incubator at 37 ^o^C, and 5 to 7-day-old gliospheres were used for the experiments.

Proliferation assay
-------------------

The effect of PPAR*γ* agonists on the proliferation of glioma and BTSCs was measured by WST-1 (4-\[3-(4-iodophenyl)-2-(4-nitrophenyl)-2 H-5-tetrazolio\]-1,3-benzene disulphonate); Roche, Indianapolis, IN, USA) and 3H thymidine uptake assays. Briefly, T98G and BD29 glioma cells were cultured in 96-well tissue-culture plates (1 × 10^4^/200 *μ*l per well) in DMEM in the presence of 10% FBS (Invitrogen) and 1% penicillin--streptomycin in 5% CO~2~ incubator at 37 °C. T98G- and DB29-BTSCs were obtained by dissociating 5 to 7-day-old gliospheres generated as above by treatment with Accutase (Sigma Chemicals, St Louis, MO, USA) for 15 min at 37 ^o^C. The BTSCs were cultured in 96-well tissue culture plates (1 × 10^4^/200 *μ*l per well) in NBM in the presence of B27 and 10 ng ml^−1^ EGF+bFGF in 5% CO~2~ incubator at 37 ^o^C. Different concentrations of PPAR*γ* agonists, ciglitazone (CalBiochem, San Diego, CA, USA) or 15d-PGJ2 (Sigma Chemicals), were added at the initiation of culture and compared with the DMSO-treated control. The WST-1 reagent (10 *μ*l per well) was added at 46 h, and the OD was measured at 450 nm after 48 h using a titre-plate reader (Alpha Diagnostics, San Antonio, TX, USA). 3H thymidine (0.5 *μ* Ci per well) was added at 24 h, and cells were harvested after 48 h using a Tomtec 96 harvester (Tomtec, Hamden, CT, USA). The amount of 3H thymidine uptake was measured using Wallac Microbeta liquid scintillation counter (Perkin Elmer, Fremont, CA, USA).

Quantitative reverse-transcription PCR
--------------------------------------

The effect of PPAR*γ* agonists on the expression of stemness and differentiation genes in BTSCs was determined by quantitative reverse-transcription PCR (qRT--PCR) technique. Briefly, T98G- and DB29-BTSCs were cultured in NBM with 10 ng ml^−1^ EGF and bFGF with different concentrations of ciglitazone or 15d-PGJ2 at 37 ^o^C for 24 h. Total RNA was extracted using RNeasy kit according to the manufacturer\'s instructions (Qiagen, Valencia, CA, USA). Equal amount of RNA was reverse transcribed into cDNA, and qRT−PCR was performed using 384-well TaqMan Low-Density Human Stem Cell Gene Array Card in 7900 HT fast Real-time PCR system (Applied Biosystems, Foster City, CA, USA). To examine the mRNA expression of *Sox2* and *Nanog*, RNA samples were reverse transcribed into cDNA, using random primer and master mix from TaqMan reverse transcription kit (Applied Biosystems, Branchburg, NJ, USA). The cDNA samples were then amplified in TaqMan Universal Master Mix with optimised concentrations of Sox2 and Nanog primer sets in a standard optical 96-well reaction plate. Results were analysed using Prism 7900 relative quantification (ΔΔCt) study software (Applied Biosystems, Foster City, CA, USA). Heat map was constructed using the DataAssist software (Applied Biosystems, Foster City, CA, USA). Box plot, scatter plot, and Venn diagrams were generated using GraphPad Prism 5.0 software (GraphPad, La Jolla, CA, USA).

SDS--PAGE and western blot analysis
-----------------------------------

The effect of PPAR*γ* agonists on the expression of proteins in BTSCs was determined by SDS--PAGE and western blotting. Briefly, T98G- and DB29-BTSCs were cultured in NBM with 10 ng ml^−1^ EGF+bFGF in the presence of different concentrations of ciglitazone or 15d-PGJ2 at 37 ^o^C for 24 h. Cells were washed in ice-cold PBS, and whole-cell lysates were prepared by boiling in lysis buffer (0.2 M Tris−HCl pH 6.8, 0.8 *μ*g ml^−1^ SDS, 4% glycerol, 0.588 ℳ *β*-mercaptoethanol, 0.05 ℳ EDTA, 8 *μ*g ml^−1^ bromophenol blue) for 5 min. Total protein was resolved on 10% SDS--PAGE using a mini-gel apparatus (BioRad, Hercules, CA, USA) and transferred to a nylon/PVDF membrane (Millipore, Bedford, MA, USA) using a Novablot transfer system (Pharmacia, Piscataway, NJ, USA). The residual binding sites in the membrane were blocked by incubating with PBST (PBS and 0.1% Tween 20) containing 5% non-fat dry milk powder for 1 h. The blots were incubated with rabbit anti-Sox2, rabbit anti-Nanog, goat anti-glial fibrillary acidic protein (GFAP), rabbit anti-chondroitin sulphate proteoglycan 4 (NG2), mouse anti-*β*-III Tubulin, mouse anti-CD133, or mouse anti-*β*-actin antibody (1 : 500, Santa Cruz Biotechnology, Santa Cruz, CA, USA) in PBST containing 1% non-fat milk powder at room temperature for 1 h. Membranes were then washed in PBST and incubated with corresponding peroxidase-conjugated anti-IgG antibody (1 : 2500, Santa Cruz Biotechnology) in PBS containing 1% milk powder for 1 h. The blots were then developed using Super-signal West-pico chemiluminescence reagent (Thermo Scientific, Rockford, IL, USA).

Immunostaining and flow cytometry
---------------------------------

The effect of PPAR*γ* agonists on the expansion of CD133^+^, Sox2^+^ or Nanog^+^ BTSCs was analysed by immunostaining and flow cytometry. T98G- and DB29-BTSCs were cultured in 12-well tissue-culture plates in NBM with B27 and 10 ng ml^−1^ EGF+bFGF in the absence or presence of 10 *μ*ℳ ciglitazone or 15d-PGJ2 in 5% CO~2~ incubator at 37 °C. After 24 or 48 h, BTSCs were dissociated using Accutase for 15 min at 37 ^o^C and suspended in PBS containing 0.1% BSA. Cells were washed, fixed, and permeabilised using BD Cytofix/Cytoperm solution (BD Bioscience Pharmingen, San Diego, CA, USA) at room temperature for 15 min. The BTSCs were washed and incubated with PE-conjugated anti-CD133 antibody (1 : 10, Miltenyi Biotec, Auburn, CA, USA) in PBS with 0.1% BSA for 1 h. Cells were also stained with anti-Nanog or anti-Sox2 antibody (1 : 100, Santa Cruz Biotechnology) in BD Perm/Wash buffer at 4 °C for 1 h. Cells were then washed and incubated with DyLight 633-conjugated secondary antibody (1 : 200, Thermo Scientific) at 4 ^o^C for 30 min. DyLight 633 (1 : 200) and PE-conjugated mouse IgG1 antibody (1 : 10, Miltenyi Biotec) were used as isotype controls. The percentage of CD133^+^, Sox2^+^, or Nanog^+^ BTSCs was analysed using FACS Calibur Flow Cytometer with CellQuest software (BD Biosciences, San Jose, CA, USA).

For immunostaining, T98G and DB29 gliospheres were fixed in 1% paraformaldehyde, washed, and stained with PE-conjugated anti-CD133 antibody (1 : 10, Miltenyi Biotec) in PBS with 0.1% BSA at 4 °C for 1 h. Gliospheres were also stained with anti-Sox2 and anti-Nanog antibody (1 : 100, Santa Cruz Biotechnology) in BD Perm/Wash buffer at 4 °C for 30 min, followed by incubation with DyLight 594-conjugated secondary antibody (1 : 2000, Thermo Scientific) at 4 ^o^C for 30 min. DyLight 594-conjugated secondary antibody (1 : 2000) and PE-conjugated mouse IgG1 antibody (1 : 10, Miltenyi Biotec) were used as isotype controls. Gliospheres were mounted on a glass slide using Vectashield mounting medium with DAPI (Vector Laboratories, Burlingame, CA, USA) and photographed using Leica Leitz DMRB fluorescent microscope (Leica Microsystems, Buffalo Grove, IL, USA).

Statistical analysis
--------------------

The data was analysed by one-way ANOVA using the GraphPad Prism 5.0 software. The values are mean±s.d./s.e.m., and the significance is expressed as \**P*\<0.05, \*\**P*\<0.01, and \*\*\**P*\<0.001 in the figures.

Results
=======

Peroxisome proliferator-activated receptor gamma agonists inhibit the proliferation of glioma and BTSCs in culture
------------------------------------------------------------------------------------------------------------------

To investigate the use of PPAR*γ* agonists for the treatment of glioblastoma, we first examined the effect of PPAR*γ* agonists on the viability of glioma cells in culture. As shown in [Figure 1A and B](#fig1){ref-type="fig"}, addition of a PPAR*γ* agonist, ciglitazone or 15d-PGJ2, resulted in a dose-dependent decrease in T98G glioma viability, reaching a significant effect at 5 *μ*ℳ. Similarly, PPAR*γ* agonists also induced a dose-dependent inhibition of cell viability in DB29 primary human glioma in culture ([Figure 1C and D](#fig1){ref-type="fig"}). Both T98G and DB29 glioma cells showed comparable inhibitory response to ciglitazone and 15d-PGJ2 in culture.

To determine the potential use of PPAR*γ* agonists for BTSC-targeted therapy in glioblastoma, we then examined the proliferation of BTSCs using the WST-1 assay. We found that *in vitro* culture of BTSCs isolated from T98G and DB29 glioma grew and expanded in NBM supplemented with EGF+bFGF. Interestingly, addition of 1, 5, 10, and 25 *μ*ℳ ciglitazone or 15d-PGJ2 resulted in a dose-dependent inhibition of proliferation of both T98G- and DB29-BTSCs in culture ([Figure 1](#fig1){ref-type="fig"}). To confirm the results, we then examined the proliferation of BTSCs using the 3H thymidine uptake assay. As shown in [Figure 1](#fig1){ref-type="fig"}, addition of 1, 5, 10, and 25 *μ*ℳ PPAR*γ* agonists resulted in a dose-dependent inhibition of proliferation of both T98G- and DB29-BTSCs. These findings highlight the use of PPAR*γ* agonists for BTSC-targeted therapy in glioblastoma.

Peroxisome proliferator-activated receptor gamma agonists inhibit CD133^+^ BTSC expansion and promote differentiation
---------------------------------------------------------------------------------------------------------------------

To determine the effect of PPAR*γ* agonists on BTSCs, we examined the expression of CD133, an important stemness marker, in T98G- and DB29-BTSCs. We found that *in vitro* treatment with PPAR*γ* agonists significantly reduced the percentage of CD133^+^ cells ([Figure 2A and B](#fig2){ref-type="fig"}). The T98G glioma cells cultured in DMEM showed 4.24% CD133^+^ cells with a mean fluorescent intensity (MFI) of 76.68, whereas T98G-BTSCs cultured in NBM showed 73.68% CD133^+^ cells with an MFI of 113.60 ([Figure 2A](#fig2){ref-type="fig"}). The percentage of CD133^+^ cells in T98G-BTSCs decreased to 41.47 and 35.24% with an MFI of 114.04 and 78.44 following treatment with ciglitazone and 15d-PGJ2, respectively. Similarly, DB29 glioma cultured in DMEM showed 8.98% CD133^+^ cells with an MFI of 70.58, whereas DB29-BTSCs cultured in NBM showed 34.64% CD133^+^ cells with an MFI of 84.06 ([Figure 2B](#fig2){ref-type="fig"}). Treatment of DB29-BTSCs with ciglitazone and 15d-PGJ2 also reduced the percentage of CD133^+^ cells to 28.56 and 25.55% with an MFI of 56.78 and 68.04, respectively.

Western blot analyses showed that gliospheres express detectable levels of CD133 that decreased after treatment with PPAR*γ* agonists in culture ([Figure 3](#fig3){ref-type="fig"}). To examine if the inhibition of stemness marker CD133 was associated with an increase in the expression of differentiation markers, we treated T98G- and DB29-BTSCs with ciglitazone or 15d-PGJ2 for 24 h, and analysed their protein expression by western blot. As shown in [Figure 3E](#fig3){ref-type="fig"}, we found that T98G glioma cells expressed detectable level of astrocyte marker GFAP that decreased in T98G-BTSCs and increased after treatment with 10 *μ*ℳ ciglitazone or 15d-PGJ2. DB29 glioma and BTSCs showed low expression of GFAP that also increased after treatment with ciglitazone or 15d-PGJ2 ([Figure 3E](#fig3){ref-type="fig"}). We have also found that both T98G and DB29 glioma cells expressed early oligodendrocyte marker NG2 that decreased in BTSCs and increased after treatment with PPAR*γ* agonists, but more so in DB29-BTSCs than T98G-BTSCs ([Figure 3E](#fig3){ref-type="fig"}). The expression of neuronal marker *β*-III Tubulin was not detected in T98G- and DB29-BTSCs cultured in the absence or presence of PPAR*γ* agonists. These results suggest that PPAR*γ* agonists induce glial differentiation of BTSCs in glioma.

Peroxisome proliferator-activated receptor gamma agonists alter the expression of differentiation genes in BTSCs
----------------------------------------------------------------------------------------------------------------

To further define the molecular mechanisms of PPAR*γ* agonists, we then examined the effect of ciglitazone on the expression of 50 differentiation genes in DB29- and T98G-BTSCs using the TaqMan Low-Density Human Stem Cell Gene Array Card (384 wells). As shown in [Figure 3A](#fig3){ref-type="fig"}, the heat map shows significant changes in the gene expression profile of DB29- and T98G-BTSCs after treatment with ciglitazone ([Figure 3A](#fig3){ref-type="fig"}). Box-plot and scatter-plot analyses also showed significant alteration in the expression of various differentiation genes in DB29- and T98G-BTSCs after treatment with ciglitazone in culture ([Figure 3B and C](#fig3){ref-type="fig"}). As presented in [Table 1](#tbl1){ref-type="table"}, DB29-BTSCs showed a⩾100-fold increase in the transcription of 10- and 1 to 100-fold increase in 14 differentiation genes, whereas 3 differentiation genes went from ND to D (not detected to detected). DB29-BTSCs also showed a 1 to 10-fold decrease in 4 and 10 to 100-fold decrease in 5, whereas 11 differentiation genes went from D to ND. The T98G-BTSCs showed⩾100-fold increase in the expression of 4 and a 1 to 100-fold increase in 7, whereas 9 differentiation factors went from ND to D after treatment with ciglitazone. The T98G-BTSCs also showed a 1 to 100-fold decrease in 12 and a⩾100-fold decrease in 11, whereas 6 differentiation genes went from D to ND. We have also found that three differentiation genes (*COL1A1, IAPP*, and *NEUROD1*) were not detected (ND to ND) before and after treatment with ciglitazone in DB29-BTSCs, whereas *DDX4* is the only differentiation gene not detected before and after treatment with ciglitazone in T98G-BTSCs ([Table 1](#tbl1){ref-type="table"}).

Further analyses showed that the *in vitro* treatment with ciglitazone increased the expression of a total of 27 differentiation genes in DB29-BTSCs and 20 differentiation genes in T98G-BTSCs ([Figure 3D](#fig3){ref-type="fig"}). Among them, the expression of 11 common differentiation genes *(PECAM1, COL2A1, CGB, TH, NES, CDX2, GCM1, AFP, SST, RUNX2,* and *ISL1)* was upregulated by ciglitazone in both DB29- and T98G-BTSCs.

Peroxisome proliferator-activated receptor gamma agonists alter the expression of stemness genes in BTSCs
---------------------------------------------------------------------------------------------------------

We also analysed the expression of 40 stemness genes by qRT−PCR using TaqMan Low-Density Human Stem Cell Gene Array Card (384 wells). We found that the *in vitro* treatment with ciglitazone significantly altered the expression of stemness genes in DB29- and T98G-BTSCs compared with the DMSO-treated control cells ([Figure 3A](#fig3){ref-type="fig"}). Box-plot and scatter-plot analyses also showed significant alteration in the expression of various stemness genes in DB29- and T98G-BTSCs after treatment with ciglitazone in culture ([Figure 3B and C](#fig3){ref-type="fig"}). Interestingly, DB29-BTSCs showed⩾100-fold increase in the transcription of 9 genes and a 1 to 100-fold increase in 8 stemness genes, whereas 6 stemness genes increased from ND to D levels after treatment with ciglitazone ([Table 2](#tbl2){ref-type="table"}). DB29-BTSCs also showed a 1 to 10-fold decrease in the expression of 4 and 10 to 100-fold decrease in 4 stemness genes, whereas 4 stemness genes went from D to ND after treatment with ciglitazone. Similarly, ciglitazone-treated T98G-BTSCs showed a⩾100-fold increase in the transcription of 2 genes and a 1 to 100-fold increase in 10 stemness genes, whereas 3 stemness genes went from ND to D. Moreover, T98G-BTSCs treated with ciglitazone also showed a 1 to 10-fold decrease in the expression of 11 and a 10 to 100-fold decrease in 5 stemness genes, whereas 8 stemness genes went from D to ND. We have also found that five stemness genes (*CD9, CRABP2, IFITM1, IFITM2,* and *NR5A2*) were not detected (ND to ND) before and after treatment with ciglitazone in DB29-BTSCs, whereas two stemness genes (*GRB7, FGF4*) were not detected before and after treatment with ciglitazone in T98G-BTSCs ([Table 2](#tbl2){ref-type="table"}).

Further analyses showed that the *in vitro* treatment with ciglitazone resulted in the downregulation of a total of 12 stemness genes in DB29-BTSCs and 24 stemness genes in T98G-BTSCs ([Figure 3D](#fig3){ref-type="fig"}). Among them, the expression of eight common stemness genes *(DNMT3B, IMP2, NR6A1, GDX4, FGF5, SOX2, POU5F1,* and *UTF1)* was reduced by ciglitazone in DB29- and T98G-BTSCs. Interestingly, *Sox2* expression was inhibited by ciglitazone in both DB29- and T98G-BTSCs, whereas *Nanog* expression was increased in DB29-BTSCs while remaining relatively unchanged in T98G-BTSCs. These results indicate that the PPAR*γ* agonists differentially regulate the expression of a multitude of stemness and differentiation factors in BTSCs.

Peroxisome proliferator-activated receptor gamma agonists alter the expression of Sox2 in BTSCs
-----------------------------------------------------------------------------------------------

To understand the mechanism by which PPAR*γ* agonists inhibit the growth of BTSCs, we then examined the expression of *Sox2* mRNA by qRT−PCR analysis. As shown in [Figure 4A](#fig4){ref-type="fig"}, T98G-BTSCs cultured in NBM with EGF+bFGF expressed higher level of *Sox2* mRNA following the addition of 1 and 5 *μ*ℳ ciglitazone or 15d-PGJ2, but expressed lower levels of *Sox2* after treatment with 10 and 25 *μ*ℳ PPAR*γ* agonists. Similarly, western blot analysis also showed that the *in vitro* treatment of T98G-BTSCs with ciglitazone or 15d-PGJ2 induced the expression of Sox2 protein at 1 and 5 *μ*ℳ, but inhibited its expression back to the starting level at 10 and 25 *μ*ℳ doses. In the case of DB29-BTSCs, qRT−PCR analysis showed that cells cultured in NBM with EGF+bFGF expressed detectable levels of *Sox2* mRNA ([Figure 4B](#fig4){ref-type="fig"}). However, treatment with ciglitazone or 15d-PGJ2 resulted in a decrease of *Sox2* mRNA and protein expression in DB29-BTSCs. These results suggest that PPAR*γ* agonists may modulate the growth of BTSCs by altering the expression of Sox2.

To examine whether the inhibition of Sox2 expression was associated with a decrease in Sox2^+^ BTSCs, we then analysed the effect of PPAR*γ* agonists on the percentage of Sox2^+^ cells in culture. As shown in [Figure 4C](#fig4){ref-type="fig"}, immunofluorescence and flow cytometry analyses demonstrated that T98G-BTSCs cultured in NBM with EGF+bFGF generated gliospheres with significant number of Sox2^+^ cells. Flow cytometry analyses showed that T98G-BTSCs constitute 65% of Sox2^+^ cells with an MFI of 44 that decreased to 57, and 9% with an MFI of 15 and 16 following treatment with 10 *μ*ℳ ciglitazone and 15d-PGJ2, respectively. Similarly, DB29 gliospheres cultured in NBM with EGF+bFGF constitute 59% of Sox2^+^ BTSCs with an MFI of 58 that decreased to 30 and 21%, with an MFI of 40 and 35 following treatment with ciglitazone and 15d-PGJ2, respectively ([Figure 4D](#fig4){ref-type="fig"}). Although both PPAR*γ* agonists inhibited the expansion of Sox2^+^ BTSCs, treatment with 15d-PGJ2 resulted in a more significant inhibition of Sox2 expression in both T98G- and DB29-BTSCs. These findings suggest that PPAR*γ* agonists modulate the expansion of Sox2^+^ BTSCs in glioma.

Peroxisome proliferator-activated receptor gamma agonists alter the expression of Nanog in BTSCs
------------------------------------------------------------------------------------------------

To further examine the effect of PPAR*γ* agonists on BTSCs, we then analysed the expression of *Nanog* mRNA by qRT−PCR analysis. As shown in [Figure 5A](#fig5){ref-type="fig"}, T98G-BTSCs cultured in NBM with EGF+bFGF expressed detectable level of *Nanog* mRNA, which increased significantly after treatment with ciglitazone or 15d-PGJ2 in culture. Western blot analysis also showed that PPAR*γ* agonists upregulated the Nanog expression in T98G-BTSCs. Additionally, DB29-BTSCs cultured in NBM with EGF+bFGF expressed low levels of Nanog, which was elevated after treatment with 1, 5, 10, and 25 *μ*ℳ ciglitazone or 15d-PGJ2 in culture ([Figure 5B](#fig5){ref-type="fig"}), suggesting the alteration of Nanog expression by PPAR*γ* agonists in BTSCs.

To examine whether the induction of Nanog expression was associated with an increase in Nanog^+^ BTSCs, we then analysed the effect of PPAR*γ* agonists on the percentage of Nanog^+^ cells in culture. As shown in [Figure 5C and D](#fig5){ref-type="fig"}, immunofluorescence staining revealed the presence of Nanog expression in T98G- and DB29-BTSCs. Flow cytometry analyses showed that T98G gliospheres constitute 76% of Nanog^+^ BTSCs that remained at 76 and 74% after treatment with ciglitazone and 15d-PGJ2, respectively. However, the MFI was slightly changed, as the DMSO-treated T98G-BTSCs showed an MFI of 50 that increased to 57 and 56, following treatment with ciglitazone and 15d-PGJ2, respectively ([Figure 5C](#fig5){ref-type="fig"}). DB29 gliospheres constituted 95% of Nanog^+^ BTSCs that slightly increased to 99 and 100%, following treatment with ciglitazone and 15d-PGJ2, respectively. The DMSO-treated DB29-BTSCs showed an MFI of 36 that significantly increased to 113 and 98, following treatment with ciglitazone and 15d-PGJ2, respectively ([Figure 5D](#fig5){ref-type="fig"}). These findings suggest that PPAR*γ* agonists modulate the expansion of Nanog^+^ BTSCs in glioma.

Discussion
==========

The BTSCs represent a small fraction of self-renewing cancer cells that are resistant to therapy and responsible for brain tumour recurrence. Recent studies have established suitable conditions to expand CD133^+^ BTSCs as gliospheres in culture ([@bib10]; [@bib9]). The EGF and bFGF are two important growth factors that are commonly used to maintain the self-renewal and multipotency of BTSCs. Growing evidence suggests that deregulated signalling pathways contribute to the continuous expansion of self-renewing CSCs in tumour ([@bib31]; [@bib14]; [@bib22]). Many glioma patients express elevated levels of EGF receptor, which is undetectable in normal brain ([@bib27]). Likewise, bFGF is induced during reactive gliosis ([@bib17]; [@bib18]), and its overexpression seems prevalent in glioma ([@bib29]; [@bib28]). In this study, we have confirmed our earlier findings that PPAR*γ* agonists inhibit the EGF- and bFGF-induced growth and expansion of BTSCs in culture ([@bib10]). We have also found that PPAR*γ* agonists inhibit CD133 expression and promote the expression of glial differentiation markers in BTSCs.

We found that the *in vitro* treatment of BTSCs with ciglitazone significantly altered the expression of various stemness and differentiation genes. One of the eight stemness factors repressed by ciglitazone in both DB29- and T98G-BTSCs is DNA (cytosine-5-)-methyltransferase 3 beta (*DNMT3B*). The *DNMT3B* has been shown to be elevated in glioma patients compared with normal brain ([@bib24]). Similarly, growth differentiation factor 3 (*GDF3*) is another stemness gene repressed by ciglitazone in both DB29- and T98G-BTSCs. This is significant, because an earlier study showed that *GDF3* induces the progression of melanoma in mice ([@bib24]), suggesting that the repression of *GDF3* may contribute to the inhibition of BTSC growth by PPAR*γ* agonists. An earlier report also showed that *FGF5* is important in the progression of malignant glioma ([@bib2]). In this study, we found that ciglitazone inhibits *FGF5* expression in both DB29- and T98G-BTSCs, suggesting its contribution to the regulation of BTSCs by PPAR*γ* agonists.

Among the 90 genes examined in this study, we focused on the altered expression of *Sox2* and *Nanog* by PPAR*γ* agonists in BTSCs. The Sox2 is a key member of the Sox (SRY-like HMG box) family of transcription factors and is essential in maintaining ESC pluripotency ([@bib6]; [@bib40]). Along with Oct3/4, Sox2 regulates transcription of development-related genes and its own transcription via both positive and negative feedback mechanisms ([@bib35]). It has been implicated in the pathogenesis of several cancers, including pulmonary, oesophageal, gastric, breast, pancreatic, and rectal cancer ([@bib25]; [@bib38]; [@bib36]; [@bib11]; [@bib32]; [@bib43]). It is also overexpressed in malignant glioma, whereas minimally expressed in normal tissues ([@bib41]). Silencing of Sox2 expression in BTSCs resulted in reduced growth and tumourigenicity in animal models ([@bib19]). Earlier studies have shown that a partial reduction or elevation in Sox2 expression can lead to ESC differentiation, suggesting existence of a complex regulatory mechanism ([@bib12]). In this study, we found that PPAR*γ* agonists caused a slight upregulation of Sox2 at lower doses of PPAR*γ* agonists and an inhibition of Sox2 at higher doses in both T98G- and DB29-BTSCs, with an exception being DB29-BTSCs treated with 15d-PGJ2 that showed a reduction of Sox2 expression at all doses. A reduction of Sox2 expression observed in this study suggests that this could be a mechanism by which PPAR*γ* agonists regulate the growth and differentiation of BTSCs in glioblastoma.

Similarly, Nanog is a homeobox transcription factor that has a critical role in maintaining the self-renewal and pluripotency of ESCs during development ([@bib47]; [@bib46]; [@bib50]). Interestingly, earlier studies have demonstrated the presence of Nanog in human glioma-derived BTSCs, suggesting its significance to the self-renewal of BTSCs in glioblastoma ([@bib21]). In this study, we found that PPAR*γ* agonists induce Nanog expression in both DB29- and T98G-BTSCs. In ESCs, overexpression of Sox2 can repress Nanog as well as itself through feedback inhibition ([@bib35]). The direct link between Sox2 repression and Nanog upregulation by PPAR*γ* agonists in BTSCs is yet to be determined. However, the differential regulation of Sox2 and Nanog by PPAR*γ* agonists observed in this study suggests a critical role for these stemness factors in modulating growth and differentiation of BTSCs in glioma. Hence, our future studies will explore the mechanisms by which PPAR*γ* agonists regulate differentiation and self-renewal of BTSCs.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

The authors declare no conflict of interest.

![Inhibition of glioma and BTSC proliferation by PPAR*γ* agonists. T98G (**A** and **B**) and DB29 (**C** and **D**) glioma and BTSCs were cultured in DMEM or NBM in the presence of ciglitazone (**A** and **C**) or 15d-PGJ2 (**B** and **D**). Cell viability and proliferation were determined using WST−1 and 3H thymidine-uptake assays. Chemical structures (inserts) of ciglitazone and 15d-PGJ2 were created using ChemDraw software (CambridgeSoft, Cambridge, MA, USA). Values are mean of triplicates (±s.d.) and \**P*\<0.05, \*\**P*\<0.01 and \*\*\**P*\<0.001 were considered significant. The figure is a representative of three independent experiments.](bjc2012161f1){#fig1}

![Inhibition of CD133 expression in BTSCs by PPAR*γ* agonists. T98G (**A**) and DB29 (**B**) glioma and BTSCs were cultured in DMEM or NBM in the presence of ciglitazone or 15d-PGJ2 for 48 h. Cells were dissociated and stained with PE-conjugated anti-CD133 antibody or isotype control. The percentage of CD133+ cells and mean fluorescent intensities (MFI) in parentheses were calculated using CellQuest software. Gliospheres were also stained with PE-conjugated anti-CD133 antibody or isotype control with DAPI and photographed ( × 100 or × 400) under a fluorescent microscope. Scale bars represent 100 and 25 *μ*m. The figure is a representative of four independent experiments.](bjc2012161f2){#fig2}

![Alteration of differentiation and stemness genes in BTSCs by PPAR*γ* agonists. T98G- and DB29-BTSCs were cultured in NMB in the presence of 10 *μ*ℳ ciglitazone. Total RNA was extracted after 24 h, and the gene expression profile determined by qRT−PCR using TaqMan low-density optical 384-well human stem cell gene panel. Gene expression in DB29- and T98G-BTSCs was normalised to 18S and GAPDH, respectively. The heat map (**A**) was constructed using DataAssist software. Box plots (**B**), scatter plots (**C**), and Venn diagrams (**D**) were generated using GraphPad Prism 5.0 software. The differentiation genes and stemness genes are shown in red and green, respectively. Lines in the box plots represent the median and the numbers represent the mean. (**E**) Total cell lysates were prepared from T98G and DB29 glioma, and BTSCs treated with 10 *μ*ℳ ciglitazone or 15d-PGJ2 for 24 h, and the expression of GFAP, NG2, *β*−III Tubulin, CD133, and *β*-actin was determined by western blot. Numbers represent the relative quantities of protein calculated using *β*-actin as internal control. The figure is a representative of two independent experiments.](bjc2012161f3){#fig3}

![Modulation of Sox2 expression by PPAR*γ* agonists in BTSCs. T98G-BTSCs (**A** and **C**) and DB29-BTSCs (**B** and **D**) were cultured in NBM with EGF+bFGF in the presence of 0, 1, 5, 10, and 25 *μ*ℳ ciglitazone or 15d-PGJ2 for 24 h. Sox2 mRNA expression was determined by qRT−PCR, and the values are presented as fold change (RQ) compared with DMSO control. Sox2 protein expression was determined by western blot and quantified using *β*-actin as internal control. T98G (**C**) and DB29 gliospheres (**D**) were stained with anti-Sox2 antibody followed by DyLight 594-conjugated second antibody and photographed ( × 100 or × 400) under a fluorescent microscope. Scale bars represent 100 and 25 *μ*m. T98G and DB29 glioma and BTSCs (**C** and **D**) were stained with anti-Sox2 antibody followed by DyLight 633-conjugated second antibody or isotype control and analysed by flow cytometry. Histograms show isotype control (blue), DMSO (red), and either ciglitazone or 15d-PGJ2 (green), with mean fluorescent intensities (MFI) in parenthesis. Values are mean of triplicates (±s.e.m.) and \*\**P*\<0.01 and \*\*\**P*\<0.001 were considered significant. The figure is a representative of three independent experiments.](bjc2012161f4){#fig4}

![Modulation of Nanog expression by PPAR*γ* agonists in BTSCs. T98G-BTSCs (**A** and **C**) and DB29-BTSCs (**B** and **D**) were cultured in NBM with EGF+bFGF in the presence of 0, 1, 5, 10, and 25 *μ*ℳ ciglitazone or 15d-PGJ2 for 24 h. Nanog mRNA expression was determined by qRT−PCR, and the values are presented as fold change (RQ) compared with DMSO control. Nanog protein expression was determined by western blot and quantified using *β*-actin as internal control. T98G (**C**) and DB29 gliospheres (**D**) were stained with anti-Nanog antibody followed by DyLight 594-conjugated second antibody and photographed ( × 100 or × 400) under a fluorescent microscope. Scale bars represent 100 and 25 *μ*m. T98G and DB29 glioma and BTSCs (**C** and **D**) were stained with anti-Nanog antibody followed by DyLight 633-conjugated second antibody or isotype control and analysed by flow cytometry. Histograms show isotype control (blue), DMSO (red), and either ciglitazone or 15d-PGJ2 (green), with mean fluorescent intensities (MFI) in parenthesis. Values are mean of triplicates (±s.e.m.) and \**P*\<0.05 and \*\*\**P*\<0.001 were considered significant. The figure is a representative of three independent experiments.](bjc2012161f5){#fig5}

###### Expression of differentiation factors in PPAR*γ* agonist treated-BTSCs

  **Symbol**                    **Gene name**                    **DB29-BTSC**  **T98G-BTSC**
  ------------ ------------------------------------------------ --------------- ---------------
  *CDH5*                      Cadherin 5 type 2                      ND--D      0.01
  *PECAM1*       Platelet/endothelial cell adhesion molecule         ND--D      100.2
  *MYF5*                      Myogenic factor 5                      ND--D      DND
  *COL2A1*                 Collagen type II alpha 1              3.3 × 10^15^   3.917
  *CGB*            Chorionic gonadotropin beta polypeptide       1.5 × 10^14^   47.2
  *HLXB9*            Motor neuron and pancreas homeobox 1         2.9 × 10^7^   0.004
  *IPF1*              Pancreatic and duodenal homeobox 1          2.1 × 10^5^   0.02
  *SERPINA1*          Serpin peptidase inhibitor clade A             5700       0.018
  *TH*                       Tyrosine hydroxylase                    3800       9.0 × 10^12^
  *PAX6*                         Paired box 6                        2600       0.405
  *INS*                            Insulin                           948.6      0.005
  *HBB*                        Haemoglobin beta                      319.9      D--ND
  *NES*                             Nestin                           307.0      129.8
  *EOMES*                        Eomesodermin                        64.65      0.001
  *T*                        Brachyury homologue                     54.75      D--ND
  *CDX2*                    Caudal type homeobox 2                   46.92      ND--D
  *MYOD1*                 Myogenic differentiation 1                 29.23      D--ND
  *GCM1*               Glial cells missing homologue 1               27.06      2.017
  *LAMB1*                       Laminin beta 1                       26.43      0.519
  *AFP*                       Alpha fetoprotein                      23.42      ND--D
  *SST*                          Somatostatin                        22.68      5.876
  *GFAP*               Glial fibrillary acidic protein               19.27      0.003
  *RUNX2*            Runt-related transcription factor 2             16.49      ND--D
  *SYP*                         Synaptophysin                       16.008      0.83
  *ISL1*          Insulin gene enhancer, ISL LIM homeobox 1          4.074      ND--D
  *ACTC1*                Actin alpha cardiac muscle 1                1.736      0.421
  *FN1*                         Fibronectin 1                        1.597      0.155
  *WT1*                         Wilms tumour 1                       0.761      9.887
  *FOXA2*                      Forkhead box A2                       0.23       ND--D
  *NPPA*                    Natriuretic peptide A                    0.14       ND--D
  *OLIG2*       Oligodendrocyte lineage transcription factor 2       0.118      0.006
  *HBZ*                        Haemoglobin zeta                      0.086      D--ND
  *GCG*                            Glucagon                          0.066      0.886
  *GATA4*                   GATA-binding protein 4                   0.066      ND--D
  *SYCP3*               Synaptonemal complex protein 3               0.037      0.039
  *PAX4*                         Paired box 4                        0.025      0.073
  *CD34*                        CD34 molecule                        D--ND      0.067
  *DDX4*           DEAD (Asp-Glu-Ala-Asp) box polypeptide 4          D--ND      ND--ND
  *DES*                             Desmin                           D--ND      0.626
  *FLT1*        Vascular endothelial growth factor receptor 1        D--ND      0.068
  *GATA6*                   GATA-binding protein 6                   D--ND      0.001
  *KRT1*                          Keratin 1                          D--ND      1.547
  *LAMA1*                      Laminin alpha 1                       D--ND      1.9 × 10^7^
  *LAMC1*                      Laminin gamma 1                       D--ND      ND--D
  *PTF1A*         Pancreas-specific transcription factor, 1a         D--ND      0.002
  *SOX17*           SRY (sex determining region Y)-box 17            D--ND      ND--D
  *TAT*                   Tyrosine aminotransferase                  D--ND      5.015
  *COL1A1*                 Collagen type I alpha 1                  ND--ND      0.105
  *IAPP*                  Islet amyloid polypeptide                 ND--ND      0.151
  *NEUROD1*              Neurogenic differentiation 1               ND--ND      D--ND

Abbreviations: bFGF=basic fibroblast growth factor; BTSCs=brain tumour stem cells; EGF=epidermal growth factor; PPAR*γ=*peroxisome proliferator-activated receptor gamma; qRT-PCR=quantitative reverse-transcription PCR. T98G and DB29-BTSCs were cultured in NMB with EGF+bFGF in the presence of 10 *μ*ℳ ciglitazone. Total RNA was extracted after 24 h and the gene expression profile was determined by qRT--PCR using TaqMan optical 384-well human stem cell gene panel. Gene expression was normalised to *18S* and *GAPDH* in DB29-BTSCs and T98G-BTSCs, respectively. The fold change (RQ) in the differentiation gene expression profile compared with DMSO control was calculated and presented in the table. The genes were arranged according to the expression levels in DB29-BTSCs from high to low. D=detected; ND=not detected. The data is a representative of two independent experiments.

###### Expression of stemness factors in PPAR*γ* agonist treated-BTSCs

  **Symbol**                        **Gene name**                        **DB29-BTSCs**  **T98G-BTSCs**
  ------------ -------------------------------------------------------- ---------------- ----------------
  *SFRP2*                Secreted frizzled-related protein 2                 ND--D       0.883
  *TDGF1*              Teratocarcinoma-derived growth factor 1               ND--D       4.455
  *FOXD3*                          Forkhead box D3                           ND--D       1.063
  *NANOG*                           Nanog homeobox                           ND--D       0.969
  *ZFP42*                  Zinc finger protein 42 homologue                  ND--D       5.043
  *PTEN*                   Phosphatase and tensin homologue                  ND--D       0.73
  *LEFTB*                 Left-right determination factor 1               1.4 × 10^6^    0.064
  *BRIX*                  Biogenesis of ribosomes homologue                   7500       0.331
  *TERT*                   Telomerase reverse transcriptase                   2300       0.756
  *LIFR*              Leukaemia inhibitory factor receptor alpha              2200       57.99
  *GRB7*                Growth factor receptor-bound protein 7                2000       ND--ND
  *FGF4*                      Fibroblast growth factor 4                      1900       ND--ND
  *GBX2*                    Gastrulation brain homeobox 2                    740.5       142.3
  *XIST*                    X-inactive specific transcript                   318.1       2.099
  *NODAL*                          Nodal homologue                           130.8       D--ND
  *NOG*                                 Noggin                               54.12       D--ND
  *COMMD3*                     COMM domain containing 3                      37.06       D--ND
  *GAL*                         Galanin prepropeptide                        35.94       D--ND
  *EBAF*                  Left-right determination factor 2                  27.29       D--ND
  *LIN28*                         Lin-28 homologue A                         24.44       0.028
  *GABRB3*            Gamma-aminobutyric acid A receptor beta 3              16.84       0.102
  *REST*                  RE1-silencing transcription factor                 13.23       1.3 × 10^4^
  *IL6ST*                  Interleukin 6 signal transducer                   3.799       0.005
  *SEMA3A*           Short basic domain-secreted (semaphorin) 3A             0.594       19.079
  *DNMT3B*            DNA (cytosine-5-)-methyltransferase 3 beta             0.242       0.485
  *IMP2*           IMP2 inner mitochondrial membrane peptidase-like          0.207       0.128
  *NR6A1*           Nuclear receptor subfamily 6 group A member 1            0.176       D--ND
  *KIT*            V-kit Hardy--Zuckerman 4 feline sarcoma oncogene          0.081       ND--D
  *GDF3*                   Growth differentiation factor 3                   0.048       0.199
  *FGF5*                      Fibroblast growth factor 5                     0.008       D--ND
  *SOX2*                 SRY (sex determining region Y)-box 2                0.003       D--ND
  *POU5F1*                      POU class 5 homeobox 1                       D--ND       0.706
  *PODXL*                          Podocalyxin-like                          D--ND       42.16
  *TFCP2L1*                Transcription factor CP2-like 1                   D--ND       ND--D
  *UTF1*        Undifferentiated embryonic cell transcription factor 1       D--ND       0.048
  *CD9*                              CD9 molecule                            ND--ND      ND--D
  *CRABP2*             Cellular retinoic acid-binding protein 2              ND--ND      42.61
  *IFITM1*            Interferon-induced transmembrane protein 1             ND--ND      1.252
  *IFITM2*            Interferon-induced transmembrane protein 2             ND--ND      0.844
  *NR5A2*           Nuclear receptor subfamily 5 group A member 2            ND--ND      0.013

Abbreviations: bFGF=basic fibroblast growth factor; BTSCs=brain tumour stem cells; EGF=epidermal growth factor; PPAR*γ*=peroxisome proliferator-activated receptor gamma; qRT-PCR=quantitative reverse transcription PCR. T98G and DB29-BTSCs were cultured in NMB with EGF+bFGF in the presence of 10 *μ*ℳ ciglitazone. Total RNA was extracted after 24 h, and the gene expression profile was determined by qRT--PCR using TaqMan optical 384-well human stem cell gene panel. Gene expression was normalised to *18S* and *GAPDH* in DB29-BTSCs and T98G-BTSCs, respectively. The fold change (RQ) in the stemness gene expression profile compared with DMSO control was calculated and presented in the table. The genes were arranged according to the expression levels in DB29-BTSCs from high to low. D=detected; ND=not detected. The data is a representative of two independent experiments.
